TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·November 2, 2026

Neurocrine Biosciences (NBIX): Growth Franchise With Pipeline Upside

Neurocrine Biosciences pairs a profitable commercial base with accelerating sales from INGREZZA, CRENESSITY, and newly acquired VYKAT XR. The stock screens as a Buy on strong revenue growth, solid cash generation, and a broad late-stage pipeline.

Research ReportNBIXHealthcareDrug Manufacturers - Specialty & GenericBiotech
By TickerSpark·November 2, 2026·17 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Neurocrine Biosciences (NBIX): Growth Franchise With Pipeline Upside
B+
Overall
B+
Balance Sheet
B+
Income
A-
Estimates
B
Valuation
TickerSpark AI RatingBuy
▌Investment Summary
Neurocrine Biosciences (NBIX) looks attractive right now, earning an overall grade of B+ and a Buy. The company combines a profitable commercial franchise with strong cash generation and a broad late-stage pipeline, and our fair value is $165.

Thesis

Investment thesis: Neurocrine Biosciences (NBIX) combines a profitable commercial franchise, strong cash generation, and a broad late-stage pipeline at a valuation that supports a moderate-risk Buy for medium-term investors. The company reported 2025 revenue of $2.9B, operating income of $619.1M, net income of $478.6M, and free cash flow of $748.7M. Its latest reported second-quarter 2026 revenue reached $959.0M, up 39% year over year, while non-GAAP EPS reached $2.85.

The investment case rests on three commercial assets. INGREZZA generated $716M in second-quarter 2026 sales and received raised full-year guidance of $2.825B to $2.875B. CRENESSITY produced $184M, with management reporting that approximately 15% of the estimated diagnosed patient population had received the medicine. VYKAT XR contributed $54M of recognized sales after the May 2026 acquisition of Soleno, with full-quarter pro forma sales of $94M.

The principal counterweights are product concentration, payer exposure, clinical execution, and the cash cost of the VYKAT XR acquisition. INGREZZA remains the largest revenue contributor, the company has beaten quarterly EPS estimates in 4 of the last 7 reported quarters, and cash fell to $332.4M at June 30, 2026 from $713.0M at December 31, 2025 after the $2.9B acquisition. At a quoted price of $145.53, the shares trade at 21.4 times trailing earnings and 14.9 times forward earnings.

Company Overview

Neurocrine Biosciences is a San Diego-based biotechnology company founded in 1992 and listed on NASDAQ under NBIX. Its business covers neurological, psychiatric, endocrine, and immunological disorders. The company had approximately 2,500 employees and describes its operations as one global business focused on discovering, developing, and commercializing medicines.

The commercial portfolio has moved beyond the single-product model that defined NBIX several years ago. INGREZZA treats tardive dyskinesia and chorea associated with Huntington's disease. CRENESSITY treats classic congenital adrenal hyperplasia. VYKAT XR, acquired through Soleno in May 2026, treats hyperphagia associated with Prader-Willi syndrome. The company also participates in endometriosis and uterine fibroid treatments through its collaboration with AbbVie.

▌Common Questions

Frequently asked questions

+Is NBIX stock a buy right now?
Yes, NBIX is a Buy right now. The company has a B+ overall grade, 39% year-over-year revenue growth in the latest quarter, and multiple commercial drivers led by INGREZZA, CRENESSITY, and VYKAT XR.
+What is NBIX's fair value?
NBIX's fair value is $165. We arrive at that view using the report's valuation framework that places the stock between the $130 buy level and the $190 sell level, while factoring in 14.9x forward earnings, strong 2026 guidance for INGREZZA, and the added growth contribution from VYKAT XR and CRENESSITY.
+What is driving Neurocrine's growth?
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

The annual revenue mix shows the commercial foundation clearly. Product revenue was $2.8B, or 99.1% of total 2025 revenue, while collaboration revenue was $26.6M, or 0.9%. That mix gives NBIX direct control over its main growth drivers, but it also makes execution on marketed products more important than collaboration income.

Business Segment Deep Dive

NBIX does not present multiple formal operating segments in the supplied materials. The practical business structure is a commercial portfolio divided among neuropsychiatry, endocrinology, and rare disease, supported by research and development programs in psychiatry, neurology, endocrinology, immunology, and metabolic disease.

Neuropsychiatry is anchored by INGREZZA and includes the late-stage osavampator and direclidine programs. Endocrinology includes CRENESSITY, VYKAT XR, and earlier-stage CRF-based programs. This mix creates a useful contrast: INGREZZA provides scale, CRENESSITY provides a growing rare-endocrine franchise, and VYKAT XR adds a newly acquired rare-disease product with a commercial ramp still underway.

The second-quarter 2026 product mix was led by INGREZZA at $716M, followed by CRENESSITY at $184M and VYKAT XR at $54M of Neurocrine-recognized sales. The combined portfolio exceeded $950M in quarterly product sales, a scale that helps fund the $1.1B to $1.3B annual research and development investment outlined in 2026 guidance.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

INGREZZA remains the economic engine of NBIX. The product generated $2.51B in 2025 sales, up from $2.31B in 2024 and $1.84B in 2023. Second-quarter 2026 sales of $716M increased 15% year over year, driven by record new patient additions and total prescriptions. Management raised 2026 sales guidance to $2.825B to $2.875B from the earlier $2.7B to $2.8B range.

The product addresses a substantial diagnosed movement-disorder market. NBIX estimates that tardive dyskinesia affects approximately 800,000 people in the United States, while roughly 90% of the 40,000 people with Huntington's disease develop chorea. INGREZZA has been approved for tardive dyskinesia since May 2017 and for Huntington's chorea since August 2023.

The commercial risk is concentration. INGREZZA represented the largest share of the current product portfolio, and management is still discussing Medicare access and 2027 pricing with payers. Management reported that approximately 70% of Medicare lives had coverage in 2026 and described pricing under existing contracts as relatively consistent through the second half of 2026.

Innovation & Competitive Advantage

NBIX's strongest advantage is the combination of validated biology and commercial specialization. The company has more than three decades of experience in receptor biology, a commercial field force of approximately 600 professionals, and a pipeline spanning small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.

CRENESSITY illustrates the value of that specialization. It is a first-in-class CRF-1 antagonist for classic congenital adrenal hyperplasia, launched in December 2024. Two-year data from pediatric and adult studies included improvements in cardiometabolic outcomes, bone health, quality of life, pediatric growth, androgen control, and glucocorticoid reduction. Management also cited more than 35,000 patient-weeks of exposure.

The late-stage pipeline adds meaningful optionality. Osavampator is in Phase 3 for major depressive disorder in patients with inadequate response to oral antidepressants. Direclidine is in Phase 3 for schizophrenia, with a Phase 2 bipolar mania study also underway. Management expects initial Phase 3 data for both programs in the second half of 2027.

The intellectual property profile supports durability. INGREZZA has U.S. patents expiring between 2027 and 2040, with settlements allowing generic sales beginning March 1, 2038, or earlier under certain conditions. CRENESSITY patents expire between 2035 and 2041, with additional applications covering protection that could extend at least as late as 2046.

Operations & Supply Chain

NBIX uses third-party manufacturers for INGREZZA, CRENESSITY, and clinical candidates. The company sources active pharmaceutical ingredients and other materials from multiple suppliers and uses long-term manufacturing and supply agreements. Third-party logistics providers handle packaging, warehousing, and shipment.

This outsourced model keeps capital spending modest. NBIX reported 2025 capital expenditures of $34.0M against $782.7M of operating cash flow and $748.7M of free cash flow. The tradeoff is dependence on supplier quality, manufacturing capacity, current good manufacturing practice compliance, and regulatory inspections of outside partners.

The VYKAT XR integration adds an operational workload. The acquisition closed on May 18, 2026, and management said the company expects sequential growth as it integrates its commercial, medical, and patient-support capabilities. Second-quarter pro forma sales were $94M, while Neurocrine recognized $54M because the product was owned for only part of the quarter.

Market Analysis

NBIX operates in specialty pharmaceutical markets where diagnosis, specialist access, reimbursement, and persistence matter as much as broad patient counts. INGREZZA competes in tardive dyskinesia and Huntington's chorea. CRENESSITY serves a rare endocrine disease with at least 20,000 affected people in the United States, according to the company's 2025 10-K.

CRENESSITY's early adoption data are favorable. Management reported that approximately 15% of the estimated diagnosed patient population had been prescribed the medicine, with adoption across pediatric endocrinologists, adult community endocrinologists, and centers of excellence. Reimbursement for dispensed prescriptions was approximately 80% in the second quarter.

The pipeline expands NBIX into larger patient populations. The company is developing osavampator for adults with major depressive disorder who respond inadequately to oral antidepressants, direclidine for schizophrenia and bipolar mania, and CRF-2 programs for obesity and related metabolic diseases. Those markets offer greater commercial scale than the current rare-disease products, but they also demand larger trials and broader commercial infrastructure.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

NBIX sells INGREZZA through a limited specialty network that includes specialty pharmacies, wholesale distributors, and specialty distributors. CRENESSITY is distributed through a single specialty pharmacy provider, reflecting the high-touch requirements of rare CAH treatment. These channels allow NBIX to manage patient support, reimbursement coordination, and product delivery more closely than a broad retail model.

The prescriber base is specialized. INGREZZA relies on neurology, psychiatry, and long-term-care relationships, while CRENESSITY is promoted to endocrinologists and CAH centers of excellence. Management said the CRENESSITY prescriber base had nearly tripled from the prior year, while the VYKAT XR launch is focused primarily on endocrinology providers treating Prader-Willi syndrome.

Patient persistence is an important commercial variable. Management described CRENESSITY as having high persistence and compliance. For VYKAT XR, management expects discontinuation rates to settle into a 25% to 30% range after the initial launch group works through the treatment cycle. That makes new patient additions and titration support central to the product's growth profile.

Competitive Landscape

The direct commercial competitor to INGREZZA is Teva's AUSTEDO and AUSTEDO XR, both deutetrabenazine products approved for tardive dyskinesia and Huntington's chorea. Older alternatives include XENAZINE, tetrabenazine, generic equivalents, and off-label treatments. INGREZZA's 15% year-over-year sales growth in the second quarter and record prescription levels show that competition has not prevented continued expansion.

CRENESSITY benefits from first-in-class positioning in CAH, a broad label, multiple formulations, and two-year clinical data. Management said this combination sets a high bar for competitors and for NBIX's own next-generation programs. The company is also developing a less-frequent dosing CRF-1 peptide, which reflects an effort to defend the franchise through convenience as well as efficacy.

VYKAT XR is positioned as a first-in-class, first-in-disease treatment for Prader-Willi syndrome hyperphagia. Management said the intellectual property estate extends into the mid-2040s. The competitive advantage is therefore a combination of early market position, disease-specific commercial knowledge, and the ability to apply NBIX's existing rare-endocrine infrastructure.

Macro & Geopolitical Landscape

The most direct macro risk for NBIX is drug pricing policy. Management said approximately 70% of Medicare lives had access to INGREZZA in 2026 and described ongoing payer discussions for 2027. The company also addressed Medicare Maximum Fair Price adjacency and maintained that its market leadership supports continued access through 2027 and 2028.

Regulatory exposure is present throughout the operating model. NBIX relies on third-party manufacturers subject to FDA and comparable agency inspections, while its pipeline depends on clinical and regulatory milestones. The 2026 guidance includes $1.275B to $1.325B of GAAP research and development expense, showing the scale of investment required to advance osavampator, direclidine, and earlier programs.

Geographic exposure is more limited than at many global pharmaceutical companies. INGREZZA is sold primarily in the United States, with Tanabe commercializing valbenazine as DYSVAL in Japan and REMLEAS in select Asian markets. This U.S.-centered model reduces direct foreign-exchange exposure but concentrates NBIX's reimbursement and policy risk in the U.S. market.

Balance Sheet Health

▌Premium Members Only

Cash fell to $332.4M at June 30, 2026 from $713.0M at year-end 2025 after the $2.9B VYKAT XR acquisition, even as the business continued to generate strong operating cash flow.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

2025 revenue reached $2.9B with operating income of $619.1M and net income of $478.6M, while second-quarter 2026 revenue jumped 39% year over year to $959.0M.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management lifted 2026 INGREZZA sales guidance to $2.825B-$2.875B after a second quarter that delivered $716M in sales and record new patient additions.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

At $145.53, NBIX trades at 21.4x trailing earnings and 14.9x forward earnings, leaving valuation supported but not cheap for a company with multiple growth drivers.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

The report's fair value sits at $165, above the current quote and between the $130 buy level and the $190 sell level, reinforcing a constructive but not aggressive stance.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

NBIX has evolved from a largely single-product company into a profitable specialty biopharma with three commercial growth drivers. The evidence is visible in the financial statements: revenue rose to $2.86B in 2025, free cash flow reached $748.7M, and second-quarter 2026 revenue reached $959.0M. INGREZZA remains the foundation, while CRENESSITY and VYKAT XR broaden the commercial base.

The medium-term opportunity is real but not automatic. INGREZZA must withstand payer and competitive pressure, CRENESSITY must continue expanding beyond its current 15% diagnosed-patient penetration, and VYKAT XR must convert integration work into sequential growth. The 2027 Phase 3 milestones for osavampator and direclidine add upside, but their value belongs in the opportunity set rather than in today's core earnings.

At $145.53, the shares offer a favorable balance of current profitability and pipeline optionality for a moderate-risk investor. The Buy rating and $165 fair-value estimate reflect a business with durable assets, strong cash generation, and credible growth, but also a valuation that deserves discipline rather than enthusiasm for its own sake.

Growth is being driven by INGREZZA, which produced $716M in second-quarter 2026 sales and had its full-year guidance raised to $2.825B-$2.875B. CRENESSITY added $184M in the quarter, and VYKAT XR contributed $54M of recognized sales after the Soleno acquisition.
+What are the main risks for NBIX stock?
The biggest risks are product concentration, payer exposure, and the cash cost of the VYKAT XR acquisition. INGREZZA is still the largest revenue contributor, and cash declined to $332.4M from $713.0M after the $2.9B deal.
+How strong is Neurocrine's profitability?
Neurocrine is already highly profitable, with 2025 operating income of $619.1M, net income of $478.6M, and free cash flow of $748.7M. That profitability is supported by a product-heavy revenue mix, with product revenue making up 99.1% of 2025 sales.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on NBIX

More to read

All articles
Neurocrine Biosciences, Inc. (NBIX) climbs 10% after hours
NBIX

Neurocrine Biosciences, Inc. (NBIX) climbs 10% after hours

Neurocrine Biosciences, Inc. (NBIX) climbs after hours as traders position for its Q3 2026 earnings event. Strong first-half sales growth, led by INGREZZA, CRENESSITY, and VYKAT XR, supports the move, though competition and product safety concerns remain key risks for investors.

Nov 2·5 min
Neurocrine (NBIX) is being punished for a diversification problem it is already fixing
NBIX

Neurocrine (NBIX) is being punished for a diversification problem it is already fixing

The market is discounting INGREZZA concentration and Soleno execution risk more aggressively than the operating numbers warrant. A 39% Q2 revenue jump, higher INGREZZA guidance and an 80 TickerSpark Score make this a contrarian buy-the-drawdown setup.

Jul 31·4 min
Michigan Consumer Sentiment Rebounds as Inflation Expectations Fall

Michigan Consumer Sentiment Rebounds as Inflation Expectations Fall

US consumer confidence improved in November, with the Michigan sentiment index rising to 51.5 and inflation expectations easing sharply. The rebound looks fragile, but the drop in year-ahead price expectations offers a more important signal for markets and Federal Reserve policy.

Nov 20·5 min